Cross-sectional clinical studies have demonstrated an incremental increase in FGF21 levels with increased severity of NAFLD [2]; in particular increased mRNA expression of FGF21 has been shown in hepatic biopsies [6]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.